Yerram is a urologic oncologist at Hackensack University Medical Center in New Jersey.
Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
The miR Sentinel Prostate Cancer Test is a standalone liquid biopsy urine test.
Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
The PRELUDE trial is assessing oncological outcomes with neoadjuvant 177Lu-PSMA-617 in high-risk, localized prostate cancer.
Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
The website is meant to educate patients and their caregivers on several aspects of the kidney cancer journey.
Expert discusses the promise of emerging MISTs for BPH
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk